China Bevacizumab Market Report 2021-2025 Featuring Roche Pharma (AVASTIN) Qilu Pharmaceutical (Ankeda) & Innovent Biologics (BYVASDA) -

DUBLIN--()--The "Investigation Report on the Chinese Bevacizumab Market 2021-2025" report has been added to's offering.

The sales of Bevacizumab in China will continue to grow due to market expansion. After the medical insurance negotiations in 2017, the price of AVASTIN decreased from CNY5176 to CNY1998. In 2020, the price was adjusted to CNY1500 due to the emergence of biosimilar drugs.

According to the analyst's research, the sales of Bevacizumab in the Chinese market has kept increasing since 2016. Although the growth rate has slowed down in the past two years, the CAGR from 2016 to 2020 is still as high as about 32%.

Bevacizumab is the world's first humanized monoclonal antibody for anti-tumor angiogenesis, which can be used to treat colon cancer and other solid tumors. AVASTIN, the original research drug (developed by Roche Pharma), was approved in China in 2010. In addition to Roche Pharma, Qilu Pharmaceutical and Innovent Biologics are the other two manufacturers in the Chinese market.

Until June 2020, six companies have submitted go-public applications for Bevacizumab. Therefore, as more biosimilar drugs appear in the market, the price of Bevacizumab will probably drop again in the future, which will further open up the market.

Topics Covered:

  • The impact of COVID-19 on China's bevacizumab market
  • Sales value and volume of China's bevacizumab 2016-2020
  • Competitive landscape of China's bevacizumab market
  • Prices of bevacizumab in China
  • Prices of bevacizumab in China by regions and manufacturers
  • Analysis of factors affecting the development of China's bevacizumab market
  • Prospect of China's bevacizumab market from 2021 to 2025

Key Topics Covered:

1 Relevant Concepts of Bevacizumab

1.1 Indications for Bevacizumab

1.2 Development of Bevacizumab in China

1.3 Governmental Approval of Bevacizumab in China

1.4 The Impact of COVID-19 on Bevacizumab sales in China

2 Sales of Bevacizumab in China, 2016-2020

2.1 Sales Value of Bevacizumab

2.1.1 Overall Sales Value

2.1.2 Sales Value by Region

2.2 Sales Volume of Bevacizumab

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Region

2.3 Sales of Bevacizumab by Dosage Form in China, 2016-2020

2.3.1 Injection

2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Bevacizumab Manufacturers in China, 2016-2020

3.1 Analysis of Market Share of Major Bevacizumab Manufacturers

3.1.1 Investigation on Market Share by Sales Value

3.1.2 Investigation on Market Share by Sales volume

3.2 Roche Pharma (Schweiz) AG

3.2.1 Enterprise Profile

3.2.2 Sales of AVASTIN (Roche's Bevacizumab) in China

3.3 Qilu Pharmaceutical Co., Ltd.

3.3.1 Enterprise Profile

3.3.2 Sales of Ankeda (Qilu's Bevacizumab) in China

3.4 Innovent Biologics (Suzhou) Co., Ltd.

3.4.1 Enterprise Profile

3.4.2 Sales of BYVASDA (Innovent's Bevacizumab) in China

4 Prices of Bevacizumab for Different Manufacturers in China, 2020-2021

4.1 Roche Pharma (Schweiz) AG (AVASTIN)

4.2 Qilu Pharmaceutical Co., Ltd. (Ankeda)

4.3 Innovent Biologics (Suzhou) Co., Ltd. (BYVASDA)

5 Prospect of Chinese Bevacizumab drug Market, 2021-2025

5.1 Influential Factors of Chinese Bevacizumab Market Development

5.1.1 The Impact of COVID-19 on Chinese Bevacizumab Market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Forecast on Market Size

5.3 Forecast on Market Trend

For more information about this report visit

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900